Last Updated: June 27, 2026

CLINICAL TRIALS PROFILE FOR TALIGLUCERASE ALFA

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Taliglucerase Alfa

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00712348 ↗	Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase	Completed	Pfizer	Phase 3	2008-12-01	This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy.
NCT00712348 ↗	Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase	Completed	Protalix	Phase 3	2008-12-01	This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme replacement therapy.
NCT01132690 ↗	A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease	Completed	Pfizer	Phase 4	2010-08-01	This is a multi-center, double-blind trial to assess the safety and efficacy of taliglucerase alfa in untreated subjects (2 to
NCT01132690 ↗	A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease	Completed	Protalix	Phase 4	2010-08-01	This is a multi-center, double-blind trial to assess the safety and efficacy of taliglucerase alfa in untreated subjects (2 to
NCT01411228 ↗	A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease	Completed	Pfizer	Phase 3	2011-09-01	A protocol to extend the assessment of the safety and efficacy of taliglucerase alfa in pediatric subjects (2 to
NCT01411228 ↗	A Multicenter Extension Study of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease	Completed	Protalix	Phase 3	2011-09-01	A protocol to extend the assessment of the safety and efficacy of taliglucerase alfa in pediatric subjects (2 to
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for Taliglucerase Alfa

Condition Name

Chart
Table

Condition Name for Taliglucerase Alfa
Intervention	Trials
Gaucher Disease	4
Gaucher Disease, Type 3	1
Type 1 Gaucher Disease	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for Taliglucerase Alfa
Intervention	Trials
Gaucher Disease	6
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Taliglucerase Alfa

Trials by Country

Map
Table

Trials by Country for Taliglucerase Alfa
Location	Trials
United States	4
Israel	4
Paraguay	2
South Africa	2
Turkey	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for Taliglucerase Alfa
Location	Trials
Virginia	1
New York	1
Georgia	1
Florida	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Taliglucerase Alfa

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for Taliglucerase Alfa
Clinical Trial Phase	Trials
Phase 4	3
Phase 3	3
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for Taliglucerase Alfa
Clinical Trial Phase	Trials
Completed	4
Recruiting	1
Withdrawn	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Taliglucerase Alfa

Sponsor Name

Chart
Table

Sponsor Name for Taliglucerase Alfa
Sponsor	Trials
Pfizer	6
Protalix	4
Ari Zimran	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for Taliglucerase Alfa
Sponsor	Trials
Industry	10
Other	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.